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Since the advent of antimicrobial therapy, considerable controversy has
existed as to the most appropriate method to administer antibiotics to max-
imize the killing of microorganisms, while minimizing toxicity to the patient,
the emergence of bacterial resistance, and costs. Over the past decade, data
gained from animal models of infection, in vitro pharmacokinetic (PK) and
pharmacodynamic (PD) studies, volunteer studies, and clinical trials have
enabled clinicians to establish the best mode of drug administration to
achieve these goals. This article addresses these issues with particular atten-
tion to PK-PD concepts.
Pharmacokinetic and pharmacodynamic considerations
The study of the movement of a drug from its administration site to the
place of its pharmacologic activity and its elimination from the body is
called ‘‘pharmacokinetics.’’ Factors aﬀecting the movement (kinetics) and
fate of a drug in the body are (1) release from the dosage form; (2) absorp-
tion from the site of administration into the bloodstream; (3) distribution to
various parts of the body, including the site of action; and (4) rate of elim-
ination from the body by metabolism or excretion of unchanged drug. These
processes are often referred to by using the acronym ADME: Absorption,
Distribution, Metabolism, and Excretion. The ADME parameters of
a drug are described by various terms, such as Cmax (maximum concentra-
tion of the drug in serum); Tmax (time to maximum concentration of the
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336 QUINTILIANI & QUINTILIANIdrug in serum after a dose); T½ (half-life of a drug in serum); AUC0–24hr or
AUC0- (area under the curve over 24 hours from the time of administration
to inﬁnity, representing the concentration of the drug in serum over time);
and CL (clearance of the drug from the serum), which may include renal
and nonrenal clearance.
Drug concentrations in interstitial ﬂuid drive the antibiotic into the bacte-
rium and, ultimately, to its binding site within the organism. Because
interstitial ﬂuid drug concentrations are proportional to and in rapid equilib-
rium with blood, antibiotic concentrations in serum are correlated with bac-
terial eradication. Although one cannot yet measure the drug’s concentration
directly at the site of attachment to the bacterium on the outside membrane of
the organism, serum levels still allow one to determine the concentrations of
the antibiotic that are necessary to inhibit (minimum inhibitory concentra-
tion [MIC]) or to be bactericidal (minimum bactericidal concentration
[MBC]) to microorganisms. As a result, drug concentrations in the blood
(plasma, serum) have been correlated with in vivo bacterial eradication.
Pharmacodynamics correlates the concentration of the drug with its
pharmacologic or clinical eﬀects. For an antibiotic, this correlation refers
to the ability of the drug to kill or inhibit the growth of microorganisms.
Antibiotics elicit their activity against bacteria by binding to a speciﬁc pro-
tein or structure in the organism.
For an antibiotic to eradicate an organism, three major factors must oc-
cur. First, the antibiotic must bind to its target sites in the bacterium. To
reach the binding site is no easy matter. It must penetrate the outer mem-
brane of the organism (penetration resistance); avoid being pumped out
of the membrane (eﬄux pump resistance); and remain intact as a molecule
(eg, avoid hydrolysis by b-lactamases). Once reaching its target, the antibi-
otic can still be frustrated if the binding site has changed its molecular con-
ﬁguration and now no longer allows the drug to attach. Until the antibiotic
overcomes all these obstacles, there is no detrimental eﬀect on the organism.
A range of diﬀerent binding sites has been identiﬁed including ribosomes,
penicillin-binding proteins, DNA topoisomerase-gyrase, and the cell mem-
brane itself. The crucial binding site varies with the antibiotic class. These
binding sites can be deﬁned as points of biochemical reaction within the bac-
terium, which must be properly executed to continue the cell’s life cycle. By
binding to them, the antibiotic interferes with a crucial chemical reaction
resulting in the death of the bacterium.
The second factor relates to concentration. The drug must not only at-
tach to its binding target but also must occupy an adequate number of bind-
ing sites, which is related to its concentration within the microorganism. The
third factor necessary for an antibiotic to work eﬀectively is that it should
remain at the binding site for a suﬃcient period of time for the metabolic
processes of the bacterium to be suﬃciently inhibited.
The two major determinants of bacteria killing include the concentration
and the time that the antibiotic remains on its target binding sites. The
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tibiotic’s level remains above a zero concentration over a dosing interval is
referred to as the ‘‘area under the plasma concentration curve’’ (AUC). In
essence, the AUC measures the concentration of the drug over a given
time period and reﬂects the amount of exposure of the organism to the an-
tibiotic over a dosing interval.
For certain classes of antibiotics, the major killing eﬀect against an or-
ganism is produced by either the time or the concentration of the drug at
the binding site. Of these two factors of bacterial killing, one may be so min-
imal in the killing process that it can be ignored in the prediction of a clinical
response. For instance, certain antibiotics, like b-lactams (penicillins, ceph-
alosporins, carbapenems, monobactams, and b-lactamase inhibitors), clin-
damycin, macrolides (erythromycin, clairithromycin), oxazolidinones
(linezolid), and vancomycin, use mainly time at the binding site to eradicate
organisms. Apparently, once the concentration exceeds a critical value,
which seems to be about two to four times above the MIC for an organism,
bacterial killing proceeds at a zero order rate, and increasing the drug con-
centration does not increase the microbial death rate.
As a result, these antibiotics are referred to as ‘‘concentration-indepen-
dent’’ or ‘‘time-dependent’’ antibiotics (Box 1). For these drugs, the duration
that the antibiotic’s concentration remains above their MBC or MIC
(TOMIC or MBC) in any one dosing interval becomes the best predictor of
clinical outcomes. For b-lactam antibiotics, the time above the MIC or MBC
for the drug in serum is generally proportional to that in the ﬂuid bathing the
organism (ie, the interstitial ﬂuidorwoundﬂuid in tissues) because the antibiotic
distributes to extracellular water, which is in dynamic equilibrium with serum.Box 1. Mode of bacterial killing by anti-infective agents
Time-dependent
b-Lactams (eg, penicillins, cephalosporins, carbapenems,
b-lactamase inhibitors, monobactams)
Clindamycin
Erythromycin
Clairithromycin
Linezolid
Vancomycin
Concentration-dependent
Fluoroquinolones
Aminoglycosides
Metronidazole
Amphotericin
Daptomycin
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lones, use mainly concentration at the binding site to eradicate organisms.
Unlike concentration-independent killing antibiotics, the aminoglycosides
and ﬂuoroquinolones eliminate bacteria most rapidly when their concentra-
tions are appreciably above their MICs for organisms and, hence, their type
of killing is referred to as ‘‘concentration-dependent’’ or ‘‘dose-dependent’’
(see Box 1). For these drugs, the rate of bacterial eradication rises with in-
creasing concentration up to a speciﬁc amount. After this speciﬁc concentra-
tion is achieved, increasing the concentration further does not increase the
magnitude of bacterial killing (interestingly, even concentration-dependent
antibiotics eventually behave like concentration-independent agents). If
the concentration is high enough, most bacteria die within a short time.
In these conditions, the eﬀect of the duration of drug exposure is minimal.
For concentration-dependent agents, the PD parameter of AUC/MIC or
C  T/MIC can be simpliﬁed to peak or Cmax/MIC (Fig. 1).
These concepts have been even further reﬁned. How long the concentra-
tion of a time-dependent antibiotic in serum should remain above its MIC
or MBC for pathogens in any one dosing interval remains controversial.
It is likely that this time may vary with diﬀerent pathogens, the site of infec-
tion, and imunocompetence of the patients. Nevertheless, it seems from an-
imal models of infection, in vitro PD models, volunteer studies, and clinical
trials that b-lactam antibiotics levels should remain above their MIC or
MBC for the target pathogen for at least 50% of the dosing interval to en-
sure the highest degree of bacterial eradication [1].
For agents with concentration-dependent killing, like aminoglycosides or
ﬂuoroquinolones, the best responses occur when the concentrations are
greater than or equal to 10 times above the MIC for their target organisms
at the site of infection [2]. For agents with concentration-dependent killing,
it has also been shown that clinical responses can be predicted and the peak/
MIC ratio by measuring the antibiotic’s AUC over the dosing interval and
dividing that value by its MIC against the target organism [3]. In essence,C
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Fig. 1. Pharmacokinetic and pharmacodynamic parameters aﬀecting antibiotic potency. AUC,
area under the curve; MIC, minimum inhibitory concentration.
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for antibiotics with concentration-dependent killing.Clinical application of concentration-dependent or dose-dependent
killing antibiotics
Being a concentration-dependent drug, aminoglycosides eradicate organ-
isms best when they achieve concentrations that are greater than or equal to
10 times above their MIC. In animal models of infection (including neutro-
penic animals), many more animals survive a potentially lethal challenge of
bacteria if the aminoglycoside is given as a single daily dose than when given
in divided doses on an every 8-hour basis [4]. To obtain this favorable ratio
(the typical MIC of gentamicin and tobramycin against Pseudomonas aerugi-
nosa is 2 mg/mL), the aminoglycoside should be given at a dose of 7 mg/kg
once daily but may be given even less frequently in patients with renal dys-
function based on a nomogram [5]. This 7 mg/kg dose usually achieves
a peak serum concentration of 20 mg/mL, thereby achieving the target of 10
times above the MIC for these aminoglycosides. In a meta-analysis compar-
ing once-daily aminoglycoside with intermittent dosing in immunocompetent
adults, once-daily dosing was equivalent with regard to bacteriologic cure,
but showed a trend toward reduced mortality rates and reduced toxicity [6].
Compared with intermittent dosing, once-daily dosing of aminoglycosides
has shown less rather than more damage of tissue, like the organ of Corti or
the renal tubular cells, on pathologic examination [7,8]. The ototoxocity or
nephrotoxicity of aminoglycosides correlates with tissue accumulation and
not peak concentration in serum [4]. Further advantages of once-daily
aminoglycoside dosing include reduction in supply and labor costs and the
emergence of bacterial resistance [9]. This new once-daily dosing method
for aminoglycosides based on the PD concepts mentioned previously has
emerged as the preferred dosing method, except for patients with enterococ-
cal endocarditis; pregnancy; ascites; renal dialysis; and burns (O20%).
Although ﬂuoroquinolones also exhibit concentration-dependent killing
of bacteria, excessively high serum concentrations of these agents can, un-
fortunately, be associated with seizures and other potentially serious central
nervous system adverse reactions. This has been the major reason why qui-
nolones cannot be dosed at very high concentrations. When peak/MIC
ratios of greater than or equal to 10 cannot be reached without excessive
toxicity, then time of exposure of the organism to the drug cannot be ig-
nored, and bacterial eradication again becomes a function of concentration
and time of exposure (ie, AUC/MIC).
Most of the currently available ﬂuoroquinolones given at their usual
dose, even orally, achieve urinary concentrations far above 10 times their
MIC for even diﬃcult organisms like P aeruginosa. Despite ciproﬂoxacin’s
slightly lower MIC against this bacterium compared with levoﬂoxacin and
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lones because they all attain urine concentrations greater than or equal to
10 times their MICs against this bacterium. Interestingly, the only ﬂuoroqui-
nolone that was contraindicated for the treatment of P aeruginosa urinary
tract infection was trovaﬂoxacin, because of its very low urine concentra-
tions (approximately 6 mg/mL) and its relatively high MIC (approximately
4 mg/mL) for this organism. Moxiﬂoxacin is also an unwise choice because
only 25% of active drug is eliminated in the urine. This is the reason why
microbiology laboratories do not report the susceptibility of any urinary
pathogens. The percentages of a dose of ciproﬂoxacin, levoﬂoxacin, and ga-
tiﬂoxacin eliminated in the urine are 50%, 90%, and 90%, respectively. For
evaluating the eﬃcacy of ﬂuoroquinolones, the PK-PD concept used for
predicting outcomes in urinary tract infection is the concentration in
urine/MIC greater than or equal to 10, whereas in systemic infection it is
the AUC/MIC.
An indexing of the AUC with the MIC to predict clinical response has
been used mainly with the respiratory quinolones. For instance, certain or-
ganisms require modest AUC/MIC ratio for their prompt eradication.
Streptococcus pneumoniae are typically rapidly killed by quinolones at an
AUC/MIC24hr ratio of 30 to 35, whereas others, like P aeruginosa and
most other aerobic gram-negative bacteria, require much greater exposure
to quinolones (AUC/MIC24hr ratios R100–125) to be eradicated. The
term ‘‘target attainment’’ is often used to determine the likelihood of an an-
tibiotic to attain these ratios. The necessary dose and dosing interval of an
antibiotic can be calculated to achieve these ratios that have been correlated
with favorable outcomes. Unfortunately, for some antibiotics, particularly
those with high MICs against a bacterium, these target rations either cannot
be achieved or only in a small percent of the time. These ratios should be
reported as 24-hour unbound or free drug AUC/MIC and not as total
drug because only the unbound drug is in equilibrium with its targets bind-
ing sites in the organism [10]. It should also be emphasized that it is only the
unbound or free concentrations of an antibiotic that can cross biologic
membranes (human and bacterial) and interact with target sites leading to
a biologic eﬀect (eﬃcacy or toxicity). For an antibiotic to reach its target
site in an organism it must ﬁrst penetrate through the organism’s outer
membrane. Because typically only molecules of less than 1000 d can pass
through the channels (porins) in the outer membrane, and because albumin
has a molecular weight of about 40,000 d, an antibiotic bound to albumin
has no chance of reaching its binding site.Clinical application of concentration-independent or time-dependent
killing antibiotics
For antibiotics with time-dependent or concentration-independent kill-
ing, like b-lactams, the often mentioned advice in package inserts is that
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considered to be ‘‘severe’’ as compared with those that are deemed ‘‘mild’’
or ‘‘moderate.’’ This dosing concept makes little, if any, PD or pharmacoe-
conomic sense, except possibly for infections located in body areas (eg, ce-
rebrospinal ﬂuid, vitreous humor of the eye) where the higher serum
concentrations may improve drug penetration. It should be remembered
the high serum levels of b-lactam antibiotics do not drive more drug intra-
cellularly or into ‘‘tissue’’ because these agents exhibit insigniﬁcant intracel-
lular penetration. The higher serum levels merely result in similar levels in
the interstitial ﬂuid that surround the cells and the same PK-PD concepts
that apply to serum levels also apply to interstitial concentrations. Although
there typically exists a slight lag period before interstitial and serum levels
attain equilibrium, there is a close parallel with b-lactam antibiotics between
their concentrations in serum and interstitial ﬂuid compartments. The poor
intracellular penetration of b-lactam antibiotics is the explanation why these
agents do not eradicate intracellular pathogens like Chlamydia sp, Myco-
plasma sp, and Legionella sp.
There are ﬁve major ways to prolong the duration of a b-lactam concen-
tration above its MIC for bacteria in any dosing interval: (1) use another
drug (eg, probenecid) that interferes with its elimination; (2) dose frequently;
(3) increase the dose of the antibiotic; (4) replace with another therapeuti-
cally equivalent antibiotic with a longer serum half-life; and (5) administer
by constant infusion.
Although probenecid blocks the renal tubular secretion of most b-lactam
antibiotics, it may do the same for other drugs, resulting in unexpected ad-
verse reactions. Moreover, if a patient develops a hypersensitivity reaction it
is diﬃcult, if not impossible, to determine whether the reaction was caused
by probenecid or the antibiotic.
Dosing frequently or increasing the dose is usually unacceptable in to-
day’s medical era of ﬁscal restraints because of excessive cost from high
drug acquisition costs and ancillary service time. Moreover, doubling the
dose of a b-lactam antibiotic is generally ineﬃcient, yielding an increase in
T greater than MIC of only one half-life.
Using an antibiotic with a longer half-life is sensible as long as the one
with the longer half-life is therapeutically equivalent and is not appreciably
more expensive. Examples of this type of interchange include replacing
cephalothin with cefazolin, cefoxitin with cefotetan, and cefotaxime with
ceftriaxone.
There has been a renewed interest in administering b-lactam antibiotics
by a 24-hour constant infusion because this represents an easy way using
the least amount of drug, supply, and labor costs to maintain drug concen-
trations above the antibiotic’s MIC for the entire day or 100% of the dosing
interval.
For the antipseudomonas b-lactams, constant infusion dosing methods
are an alternative dosing approach because most of these agents have
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age insert of piperacillin-tazobactam to treat nosocomial pneumonia is 4.5 g
every 4 to 6 hours. To optimize clinical outcomes, minimize toxicity, and
reduce costs in view of the PK-PD considerations mentioned previously, pi-
peracillin-tazobactam could be administered by constant infusion once
daily. In the constant infusion program at Hartford Hospital, 12 g a day
is used for a patient with suspected or proved pseudomonas infection; 9 g
a day in patients not suspected to have pseudomonas infection; and an
even lower infusion dose (based on a nomogram) if the patient has renal im-
pairment [11]. Moreover, in a study [12] comparing intermittent with con-
stant infusion ceftazidime with nosocomial pneumonia, similarities were
noted in clinical outcomes but a major reduction in costs associated with
constant infusion.
Further clinical outcomes studies are needed to conﬁrm whether this con-
stant infusion dosing method will become the preferred dosing approach for
those b-lactam antibiotics that have relatively short half-lives and require
high daily dose (eg, oxacillin, nafcillin, ceftazidime, piperacillin-tazobactam,
ticarcillin–clavulaniic acid).Volume of distribution
One of the simplest models in PK describes the body as a single homog-
enous compartment into which the drug seems to dissolve. The volume of
this compartment measured in liters per kilogram, called the apparent vol-
ume of distribution, rarely relates to physiologic volumes but serves as a pro-
portionality constant between the dose of drug administered and the
observed plasma or serum concentration just after the intravenous adminis-
tration of a bolus dose.
This concept can be more easily understood using a hydrodynamic or
‘‘bathtub’’ model. In the bathtub model, one adds a known amount of
dye to a bathtub of known volume. Clearly, a large bathtub yields a smaller
concentration than a small bathtub if the same quantity of dye is placed in
each one. Drugs that distribute widely through the body tend to have large
volumes of distribution and low serum concentrations; drugs that remain
only in the blood volume typically have small volumes of distribution and
high serum concentrations. In general, drugs with a high level of serum pro-
tein binding penetrate to a lesser extent into the interstitial spaces, produce
higher peak serum concentrations, and exhibit a slower rate of elimination
from the body, especially if the major elimination mode is by glomeruloﬁl-
tration. An inverse relationship exists between protein binding and volume
of distribution. There is no relationship between renal tubular secretion and
protein binding.
The value of volume of distribution for the clinician is that this term
roughly describes whether or not the antibiotic will be widely distributed
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typically have low (!20 L) volumes of distribution at steady state, whereas
agents with widespread tissue distribution (eg, ﬂuoroquinolones) have high
(O100 L/kg) volumes of distribution at steady state. Drugs with low volume
of distribution indicate their distribution is limited, mainly to extracellular
ﬂuids and not into tissue.Clearance
Drug concentrations decline in the body as a result of elimination, usually
from the kidneys or liver, or both. The term ‘‘clearance’’ is used to describe
the intrinsic ability of the body to remove drug. Clearance represents a the-
oretic volume of blood or plasma that is cleared or completely removed of
drug within a period of time. It is expressed as units of volume per time. The
clearance volume for a drug is generally constant during a dosing interval.
The amount of drug removed per unit of time can be determined if one re-
calls that concentration and volume are related. Because the clearance of
a drug remains constant after distribution is complete, but the serum con-
centrations decline as drug is removed from the body, the amount of drug
removed per unit of time is highest when the serum concentration is highest
(ie, just after administration of a dose).Half-life and steady-state
In the one-compartment PK model, which most antibiotics follow, drug
distribution is assumed to be instantaneous, and elimination from the body
follows ﬁrst-order (log linear) decline. A semilogarithmic plot of drug con-
centration versus time yields a linear graft. This type of plot can be used to
determine the half-life of a drug, which refers to the amount of time required
for the drug concentration to decrease by 50%. A simple rule for drugs that
follow a one-compartment model is to multiply the half-life by 5, and that
predicts the time the serum concentrations decline to their lowest or trough
concentration. Antibiotics with very short half-lives (eg, penicillin, nafcillin,
oxacillin, cephalothin) require very frequent dosing, such as every 4 hours,
because their half-lives are only 30 minutes. Now there are many antibiotics
with long half-lives, like the respiratory quinolones (eg, levoﬂoxacin, gati-
ﬂoxacin, and moxiﬂoxacin), ceftriaxone, and azithromycin, legitimizing
once-daily dosing.
If the half-life of a drug is known, one can predict the time required to
reach steady-state when all the peak and trough concentrations are the
same after the dose. Fifty percent of the ﬁnal steady-state concentration
accumulates during each half-life, so that after ﬁve half-lives, approximately
97% of the ﬁnal steady-state concentration has been achieved. For example,
an antibiotic with a half-life of 2 hours (eg, ceftazidime) takes about 10 hours
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one) reaches steady-state in about 40 hours.
The longer the half-life of a drug, the longer it takes to achieve a steady-
state concentration. This can be particularly important for patients receiving
drugs that have long half-lives and narrow therapeutic ranges of serum con-
centrations. In these patients often a loading dose is used to achieve rapidly
therapeutic drug concentrations.Postantibiotic eﬀect
The postantibiotic eﬀect (PAE) describes the persistent suppression of
bacterial growth after exposure of a microorganism to an antibiotic. The
term should not be confused with the eﬀects of bacterial suppression caused
by antibiotic subinhibitory concentrations. Antibiotics that kill bacteria by
interfering with protein synthesis (eg, aminoglycosides, chloramphenicol,
macrolides, tetracyclines) or DNA replication (eg, quinolones) usually dem-
onstrate prolonged PAEs (eg, 1–5 hours) against gram-negative bacteria,
whereas agents that kill bacteria by interfering with cell wall synthesis (eg,
b-lactam antibiotics, glycopeptides) have little, if any, PAE against these
types of organisms. The one major exception is the carbapenems (eg, imipe-
nem, meropenem) that exhibit fairly long PAEs against P aeruginosa.
Against gram-positive bacteria, both types of antibiotics typically exhibit
short PAEs of about 1 hour. The clinical relevance of the PAE is related
to its use in establishing dosage regimens that are directed against a speciﬁc
pathogen. The PAE has been one of many explanations for the success of
intermittent dosing with drugs that exhibit short half-lives.Bioavailability
The degree of absorption or bioavailability of an antibiotic has become
an extremely important PK and pharmacoeconomic property of an antibi-
otic because it often allows for inexpensive and the eﬀective treatment of
an infection without the use of injectable agents or hospitalization. More-
over, there are many other advantages to replacing an intravenous antibiotic
rapidly with an oral formulation. Probably the greatest advantage is the
avoidance of so-called ‘‘intravenous line sepsis,’’ the major source for hos-
pital-acquired bacteremias and fungemia. Proactive programs converting
patients rapidly from intravenous to oral therapy is often designated as se-
quential, transitional, or switch therapy. To replace an intravenous antibi-
otic with an oral formulation, the oral drug should have a high degree of
bioavailability, preferably over 90%. In this situation, the concentrations
of the oral antibiotic in tissue or serum can rival the levels that are obtained
if the patient is kept on the intravenous formulation. Box 2 records the oral
antibiotics that exhibit greater than or equal to 90% bioavailability.
Box 2. Oral aniti-infectives with greater than or equal to 90%
bioavailability
Levofloxacin (Levaquin)a, gatifloxacin (Tequin), moxifloxacin
(Avelox)
Metronidazole (Flagyl), clindamycin, TMP-SMX (Bactrim),
rifampina
Minocyclinea, doxycycline, fluconazole (Diflucan)a, voriconazole
(Vfend), linezolid (Zyvok)a
Cephalexin, cefadroxil, cefprozil
a 100% bioavailable.
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those oral agents with less than 50% bioavailability.Common mistakes in the interpretation of pharmacokinetic
and pharmacodynamic concepts
For decades, it has been traditional to view an antibiotic with bactericidal
activity against a pathogen as a preferable choice over one that exhibits bac-
teriostatic activity. It is now well recognized that antibiotics cannot be cat-
egorized in such a simplistic manner, because their type of activity varies
against diﬀerent pathogens and under diﬀerent conditions. Antibiotics
with bacteriostatic activity may be as eﬃcacious as ones with bactericidal ac-
tivity against an organism even in diﬃcult infections (eg, meningitis, endo-
carditis, osteomyolitis, the febrile neutropenic patient) where it has been
customary to recommend a drug that exhibits bactericidal action against
the target pathogen. It now probably makes sense for clinicians to avoid us-
ing this concept in selecting one antibiotic over another.
It must be emphasized that once target AUC/MIC ratios, peak concen-
tration/MIC ratio and t OMIC are achieved, there is no evidence that
higher values result in more rapid bacterial killing or less emergence of
bacterial resistance. Even concentration-dependent antibiotics eventually
behave like a concentration-independent agent. For instance, if one com-
pares the AUC/MIC rations of the three respiratory quinolones (levoﬂoxa-
cin, gatiﬂoxacin, moxiﬂoxacin, gemiﬂoxacin) against S pneumoniae, all
attain the target ratio of 30 to 35. Compared with moxiﬂoxacin, gemiﬂoxa-
cin, and gatiﬂoxacin, levoﬂoxacin achieves somewhat lower ratios against
this bacterium, yet, as predicted, has identical eﬃcacy in infections, like
community-acquired pneumonia, caused by this bacterium.
Excessive AUC/MIC ratios may produce unwanted adverse reactions
by disrupting the normal gastrointestinal ﬂora (collateral damage) and
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AUC/MIC ratios greater than or equal to 60 with gatiﬂoxacin have an as-
sociation with hyperglycemia [13] and the high fecal concentration with
moxiﬂoxacin has been associated with an increase in gastrointestinal coloni-
zation with Clostridium diﬃcile, vancomycin-resistant enterococci, and
Candida albicans [14].
Another common mistake is to equate an antibiotic’s potency against an
organism solely by its MIC, assuming that the antibiotic with the lowest
value has the greatest activity. It must be underscored that the MIC or
MBC of an antibiotic against a pathogen is only one of many factors that
determines the best or preferred drug to cure an infection. When determin-
ing the potency of an antibiotic against a bacterium, one must include other
items, such as protein binding, PK, distribution into the site of infection, the
adequacy of the patient’s host defenses, and the amount of exposure an or-
ganism requires to an antibiotic for its eradication. Paradoxically, microbi-
ologic reports that provide both MIC data along with susceptibility data
may actually encourage a clinician to select the wrong antibiotic because
of the tendency of clinicians to view potency only in terms of the MICs. Re-
porting systems that merely report the data in terms of sensitive, intermedi-
ate, or resistant are actually better for most clinicians because these values
are determined by an integration of the microbiologic and PK properties
of the antibiotic.
A common example of this type of mistake is the popular view by clini-
cians that ciproﬂoxacin has more activity or potency compared with levo-
ﬂoxacin against P aeruginosa based solely on its slightly lower MIC
against this bacterium (ciproﬂoxacin, approximately 0.5 mg/mL; levoﬂoxa-
cin, approximately 1 mg/mL). This slightly lower MIC of ciproﬂoxacin is
cancelled out by its lower serum concentration compared with levoﬂoxacin
resulting in no diﬀerence in potency of these two agents against this organ-
ism. At equivalent dosages for nosocomial pneumonia, levoﬂoxacin, 750 mg
intravenously every 24 hours, has a threefold higher peak serum level and
AUC24h than ciproﬂoxacin, 400 mg intravenously every 8 hours. As ex-
pected, national surveillance studies [15,16] performed over the last 7 years
comparing the susceptibility of P aeruginosa to ciproﬂoxacin and levoﬂoxa-
cin have shown no diﬀerence. In a PD study [12] comparing the likelihood of
either ciproﬂoxacin, 400 mg every 8 hours, or levoﬂoxacin, 750 mg every
24 hours, achieving a target AUC/MIC in serum of greater than or equal
to 125 against P aeruginosa, there was no signiﬁcant diﬀerence (ciproﬂoxa-
cin 61.8%; levoﬂoxacin 61.2%). These low attainment values suggest that
neither ciproﬂoxicin nor levoﬂoxacin should be given alone to treat serious
systemic P aeruginosa infection and that addition of another antipseudomo-
nas agent is required. In a large multicenter, randomized, double-blind trial
in the treatment of severe pneumonia that compared intravenous ciproﬂox-
acin with imipenem-cilastatin, the incidence of failure to eradicate P aerugi-
nosa and the development of bacterial resistance in this bacterium in
347CRITICAL CARE CLINICIANSpatients treated with monotherapy with ciproﬂoxacin was 67% and 38%,
respectively [17].Summary
The ultimate goal of antimicrobial therapy is to eradicate microbial path-
ogens at the speciﬁc site of infection. To accomplish this goal, the clinician
must become familiar with PK and PD concepts because an understanding
of this information establishes the basis for appropriate dosing strategies to
optimize clinical eﬃcacy and minimize toxicity, costs, and the emergence of
bacterial resistance. Appreciation of these concepts results in dosing of an-
tibiotics in a scientiﬁcally and economically sound fashion.References
[1] Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in deter-
mining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis
1995;22:89–96.
[2] Moore RD, Leitman PS, Smith CR. Clinical response to aminoglycoside therapy: impor-
tance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis
1987;155:93–9.
[3] DudleyMN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference
to ﬂuoroquinolones. Am J Med 1991;91(Suppl 6A):45S–50S.
[4] BennettWM, PlampCE,GilbertDN, et al. The inﬂuence of dosage regimen on experimental
nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979;140:
570–80.
[5] Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with once-daily aminoglycoside
program administered to 2184 patients. Antimicrob Agents Chemother 1995;39:650–5.
[6] Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent
adults: a meta-analysis. Ann Intern Med 1996;124:717–25.
[7] Hutchin T, Cortopassi G. Proposed molecular and cellular mechanism for aminoglycoside
ototoxicity. Antimicrob Agents Chemother 1994;38:2517–20.
[8] Tran Ba Huy P, Manuel C, Meulemans A. Kinetics of aminoglycoside antibiotics in peri-
lymph and endolymph in animals. In: Lerner SA,Matz GJ, Hawkins JE, editors. Aminogly-
coside ototoxicity. Boston: Little Brown; 1981. p. 81–97.
[9] Hitt CM,KlepserME, Nightingale CH, et al. Pharmacoeconomic impact of once-daily ami-
noglycoside administration. Pharmacotherapy 1997;17(4):810–4.
[10] Zhanel GA, Walters M, Laing N, et al. In-vitro phamacdynamic modeling simulating free
serum concentrations of ﬂuoroquinolones against multidrug resistant Streptococcus pneu-
moniae. J Antimicrob Chemother 2001;47(4):435–40.
[11] Kuti JL, Nightingale CH, Quintiliani R, et al. Pharmacodynamic proﬁling of continuously
infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analy-
sis. Diagn Microbiol Infect Dis 2002;44:51–7.
[12] NicolauDP,McNabb JC, LacyMK, et al. Pharmacokinetic and pharmacodynamics of con-
tinuous and intermittent ceftazidime during the treatment of nosocomomial pneumonia.
Clin Drug Investig 1999;2:133–9.
[13] Ambrose PG, Bhavnani SM, Cirincione BB, et al. Gatiﬂoxacin and the elderly: pharmack-
inetic-pharmacodynamic rationale for a potential age-related dose reduction. Journal of
Antimicrobial Chemotherapy 2003;552:435–40.
348 QUINTILIANI & QUINTILIANI[14] Donskey CJ, Helfand MS, Pultz NJ, et al. Eﬀect of parenteral ﬂuoroquinolone administra-
tion on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointes-
tinal tract. Antimicrob Agents Chemother 2004;48:326–8.
[15] Karlowsky JA. Trust surveillance data. Int J Antimicrob Agents 2002;18:21–31.
[16] Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in-vitro
ampliﬁcation of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;
112(2):275–85.
[17] FinkMO, SnydmanDR, NieidermanMS, et al. Treatment of severe pneumonia in hospital-
ized patients: results of a multicenter, randomized, double blind trail comparing intravenous
ciproﬂoxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob
Agents Chemother 1994;38(3):547–57.
